Helicobacter pylori infection rate in patients treated with rifampicin - Eradication effect of rifampicin on Helicobacter pylori

S. Fujimura, T. Kawamura, N. Asou, H. Takahashi, A. Watanabe

    Research output: Contribution to journalArticlepeer-review

    2 Citations (Scopus)

    Abstract

    Eradication therapy of Helicobacter pylori infection by standard proton pump inhibitor-based triple therapies (clarithromycin and amoxicillin) has been correlated with cure of peptic ulcer disease. On the other hand an increase in drug-resistant H. pylori has been reported to be a clinical problem. Thus, the aim of this study was to clarify the effect of rifampicin by susceptibility tests and in vitro inducement of drug resistance on H. pylori. In the in vivo study, anti-H. pylori IgG antibody and the [13C] urea breath test were used in a total 40 tuberculosis and atypical tuberculosis patients treated with rifampicin. The prevalence of H. pylori infection was low in the patients treated with rifampicin, and the eradication rate was 23.1%. The results of this study suggested that rifampicin eradicates H. pylori in tuberculosis and atypical tuberculosis patients treated with the drug.

    Original languageEnglish
    Pages (from-to)839-842
    Number of pages4
    JournalJapanese Journal of Chemotherapy
    Volume48
    Issue number11
    Publication statusPublished - 2000 Jan 1

    Keywords

    • Helicobacter pylori
    • Rifampicin

    ASJC Scopus subject areas

    • Pharmacology
    • Pharmacology (medical)

    Fingerprint Dive into the research topics of 'Helicobacter pylori infection rate in patients treated with rifampicin - Eradication effect of rifampicin on Helicobacter pylori'. Together they form a unique fingerprint.

    Cite this